A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

BACKGROUND: Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by selective inhibition of the urate transporter 1. We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Furuno, Kazuki, Kanda, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066279/
https://www.ncbi.nlm.nih.gov/pubmed/31970593
http://dx.doi.org/10.1007/s10157-020-01851-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066279/
https://www.ncbi.nlm.nih.gov/pubmed/31970593
http://dx.doi.org/10.1007/s10157-020-01851-6

Ejemplares similares